Recent 8-K filings for ESLA

• January 6, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements ×3

  Estrella Immunopharma raises $8.0M in registered direct offering and private placement

  Gross proceeds of $8.0M from sale of 4,063,290 shares, 1,000,000 pre-funded warrants, and 7,594,935 PIPE common warrants.

• December 4, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Estrella advances STARLIGHT-1 to Phase II after DSMB OK; 100% CR in high-dose cohort

  DSMB recommends Phase II at RP2D after no treatment-related SAEs in Phase I (n=9).

• November 6, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Estrella Immunopharma completes second dose cohort in EB103 trial; 100% CR rate

  100% complete response (CR) rate at Month 1 in all evaluable patients in second dose cohort of STARLIGHT-1 trial.

• August 7, 2025, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

  Estrella Immunopharma receives Nasdaq non-compliance notice for MVLS below $35M

  Received Nasdaq notice on Aug 1, 2025 for failing to maintain minimum MVLS of $35M for 30 consecutive business days.

• June 3, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 8.01item 9.01

  Estrella Immunopharma raises ~$3.35M in PIPE at $1.50/share

  Issued 2,233,334 shares at $1.50 each (premium to $1.00 close on May 29, 2025).

• May 2, 2025, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

  Estrella Immunopharma receives Nasdaq bid price deficiency notice; faces potential delisting

  Nasdaq notified Estrella that common stock failed to maintain $1.00 minimum bid for 30 consecutive days through April 28, 2025.

• February 21, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Estrella Immunopharma completes first dose cohort in STARLIGHT-1; DSMB approves second dose

  First cohort enrolled relapsed/refractory B-cell NHL patients who failed multiple prior therapies; no DLTs or SAEs.

• February 20, 2025, 6:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Estrella Immunopharma receives Buy rating from D. Boral Capital with $16 price target

  D. Boral Capital initiates coverage on Estrella (ESLA) with a Buy rating and 12-month price target of $16.00 per share.

• November 25, 2024, 6:59 PM ET regulatory materiality 0.75 negative item 3.01

  Estrella Immunopharma receives Nasdaq deficiency notices for low equity and low bid price

  Stockholders' equity of $746,286 as of Sep 30, 2024, below Nasdaq's $2.5M minimum.

• August 6, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Estrella Immunopharma doses first patient in Phase I/II trial for EB103 in B-cell NHL

  First patient dosed in STARLIGHT-1 Phase I/II trial of EB103, an autologous anti-CD19 ARTEMIS T-cell therapy.

• April 10, 2024, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Estrella Immunopharma posts investor presentation; EB103 Phase I expected 1H 2024

  EB103 (CD19 ARTEMIS) IND cleared Q1 2023; Phase I trial targeted for 1H 2024 in r/r B-cell lymphoma.

• March 7, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Estrella Immunopharma signs $33M clinical trial SOW with Eureka for EB103 Phase I/II NHL trial

  Total fees of $33M for 20-patient Phase I/II trial of EB103 anti-CD19 ARTEMIS T-cell therapy in R/R B-cell NHL.

Executive changes

Materiality & sentiment trend

Max materiality 0.85 · Median 0.55 · Most common event other_material

10 positive 4 negative 12 neutral

source · ESLA on sec.gov